On the recordDecember 12, 2019
I thank the gentleman for yielding. I thank the Democratic leadership for, I think the first time this year, allowing our side to actually have a substitute to a major piece of legislation. And I thank our leadership, because that substitute is not a partisan substitute but, rather, a bipartisan substitute. In fact, every single provision in this bill has got strong bipartisan support, which was packaged together. Tomorrow will mark the third anniversary of President Obama's signing of 21st Century Cures, a bill that Diana DeGette and I helped shepherd through our committee on a unanimous vote, and we passed here in the House 392-26. 21st Century Cures increased NIH funding by some $45 billion over a 10-year span. It sped up the approval of drugs and devices, and just after 3 years we have seen the number of cell, gene, and nucleoid therapies have more than doubled. In fact, research this last year will actually exceed $13 billion. The FDA is predicted to approve as many as 20 gene therapy drugs by the year 2025. That is wonderful news. We all want to do something about drug prices, and that is what a vote for our substitute, H.R. 19, will do. The President will sign that bill, but he is not going to sign this bill, H.R. 3, because it is going to slow down the ability to find the cures that we want to find for these awful diseases. Now, those aren't my words. That is the CBO, a nonpartisan group, it is the CEA, the Council of Economic Advisers.…





